0001209191-23-042551.txt : 20230718 0001209191-23-042551.hdr.sgml : 20230718 20230718160013 ACCESSION NUMBER: 0001209191-23-042551 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAGNONI PABLO J CENTRAL INDEX KEY: 0001205703 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 231094235 MAIL ADDRESS: STREET 1: ONYX PHARMACEUTICALS, INC. STREET 2: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-14 0 0000879169 INCYTE CORP INCY 0001205703 CAGNONI PABLO J 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19083 0 1 0 0 President, R&D 0 Common Stock 2023-07-14 4 A 0 9668 0.00 A 202068 D Employee Stock Option (right to buy) 61.76 2023-07-14 4 A 0 20275 0.00 A 2033-07-13 Common Stock 20275 20275 D Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Including the July 14, 2023 RSU Grant, this includes an aggregate of 202,068 shares of common stock issuable pursuant to previously reported RSUs that have not vested. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. /s/ Elizabeth Feeney, Attorney-In-Fact 2023-07-18